

Translating emerging science into real-world schizophrenia treatment

Sunday 11 October 2026 | 08:40–10:00 CEST
Room 14c



[CLICK FOR
CALENDAR INVITE](#)

Meet our faculty

Chair

Prof. Sofia Pappa

Imperial College London,
United Kingdom



Speaker

Dr. Heidi Taipale

Karolinska Institutet,
Stockholm, Sweden &
Niuvanniemi Hospital,
Kuopio, Finland



Speaker/panelist

Dr. Toby Pillinger

King's College London,
United Kingdom



Speaker/panelist

Prof. Christoph Correll

Donald and Barbara
Zucker School of Medicine
NY, USA, & Charité –
Universitätsmedizin
Berlin, Germany



Despite the expanding armamentarium of long-acting injectable antipsychotics (LAIs) formulations and dosing regimens, daily oral therapy remains the mainstay of schizophrenia care. Join us to explore the evolving role of LAIs in schizophrenia care as we consider and debate the following:

- Available evidence regarding the timing of LAI therapy and its potential impact on long-term outcomes in schizophrenia
- The importance of considering therapeutic trade-offs in the delivery of personalised antipsychotic treatment
- How clinical trial design may help elucidate the benefits and limitations of LAIs
- The role of new strategies in the future management of schizophrenia

Agenda

Prof. Sofia Pappa
08:40–08:43

Welcome and introductions

Dr. Heidi Taipale
08:43–08:55

Changing the course of schizophrenia:
why timing matters for early LAI intervention

Dr. Toby Pillinger
08:55–09:10

Personalising antipsychotic treatment
in schizophrenia: navigating therapeutic
trade-offs

Prof. Christoph Correll
09:10–09:26

From trials to trajectories: What can
contemporary LAI programs teach us about
schizophrenia outcomes?

Prof. Correll & Dr. Pillinger
Moderated by Prof. Pappa
09:26–09:48

Implementing next-generation strategies
in schizophrenia care? A structured debate

Moderated by
Prof. Sofia Pappa
09:48–10:00

Audience Q&A and close